Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2020. The document serves as a notification of major holdings pursuant to UK Disclosure Rules and Transparency Rules (DTR), rather than a financial results report.
Key Financial Metrics
The filing text does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document exclusively details a change in share ownership structure.
Material Changes
The primary material event is the acquisition of voting rights by The Capital Group Companies, Inc. ("CGC").
- Shareholder: The Capital Group Companies, Inc. (Los Angeles, CA, USA).
- Threshold Crossed: 13 May 2020.
- Notification Date: 15 May 2020.
- Total Voting Rights: 5.0803% of GSK's total voting rights.
- Share Composition:
- Ordinary Shares (GB0009252882): 208,357,778 shares (4.1530%).
- ADRs (US37733W1053): 46,524,658 shares (0.9273%).
- Financial Instruments: No voting rights held through financial instruments (0.0000%).
Management Commentary and Risks
The filing clarifies that neither CGC nor its affiliates own the reported shares for their own account. Instead, the shares are held by accounts under the discretionary investment management of CGC's subsidiaries, including Capital Research and Management Company and Capital Bank & Trust Company. No specific risks, contingencies, or unusual items related to GSK's operations are disclosed in this document.
Investor Verification Checklist
- Verify the total number of GSK voting rights outstanding (5,017,091,542) to confirm the percentage calculation.
- Confirm the breakdown of holdings between Ordinary Shares and ADRs.
- Note that this is a passive investment notification; CGC does not control the issuer.
- Check subsequent filings for any further changes in CGC's stake above the 5% threshold.